Fig. 2.

In vitro quantification of the antiviral activity of combinations of two drugs to screen high potency drug combinations against HCoV-OC43. a–d The instantaneous inhibitory potential (IIP) of combinations of nucleoside analogs and proteinase inhibitors. The concentrations of the drug combinations were normalized by IC₅₀ values. D drug concentration. e–h Experimental IIP values (IIP^com) and corresponding theoretical IIP values predicted by Bliss independence (IIP^Bcom) of double drug combinations at 4 × IC₅₀. i–l IIP^com and IIP^Bcom values of double drug combinations at 2 × IC₅₀. The columns represent one of three independent experiments. m and n The landscapes for the interaction of VV116 and nirmatrelvir against HCoV-OC43 (m) and the SARS-CoV-2 Delta variant (n). The synergy δ-score was calculated using SynergyFinder with the zero-interaction potency (ZIP) model. Each point and column bar represent one of three independent experiments